{"pmid":32371892,"title":"COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms.","text":["COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms.","Sci Data","Ostaszewski, Marek","Mazein, Alexander","Gillespie, Marc E","Kuperstein, Inna","Niarakis, Anna","Hermjakob, Henning","Pico, Alexander R","Willighagen, Egon L","Evelo, Chris T","Hasenauer, Jan","Schreiber, Falk","Drager, Andreas","Demir, Emek","Wolkenhauer, Olaf","Furlong, Laura I","Barillot, Emmanuel","Dopazo, Joaquin","Orta-Resendiz, Aurelio","Messina, Francesco","Valencia, Alfonso","Funahashi, Akira","Kitano, Hiroaki","Auffray, Charles","Balling, Rudi","Schneider, Reinhard","32371892"],"journal":"Sci Data","authors":["Ostaszewski, Marek","Mazein, Alexander","Gillespie, Marc E","Kuperstein, Inna","Niarakis, Anna","Hermjakob, Henning","Pico, Alexander R","Willighagen, Egon L","Evelo, Chris T","Hasenauer, Jan","Schreiber, Falk","Drager, Andreas","Demir, Emek","Wolkenhauer, Olaf","Furlong, Laura I","Barillot, Emmanuel","Dopazo, Joaquin","Orta-Resendiz, Aurelio","Messina, Francesco","Valencia, Alfonso","Funahashi, Akira","Kitano, Hiroaki","Auffray, Charles","Balling, Rudi","Schneider, Reinhard"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32371892","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1038/s41597-020-0477-8","topics":["Mechanism"],"weight":1,"_version_":1666138496314638336,"score":9.490897,"similar":[{"pmid":32303698,"pmcid":"PMC7186929","title":"A map of SARS-CoV-2 and host cell interactions.","text":["A map of SARS-CoV-2 and host cell interactions.","Nat Rev Immunol","Malle, Louise","32303698"],"journal":"Nat Rev Immunol","authors":["Malle, Louise"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303698","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1038/s41577-020-0318-1","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491110555648,"score":61.57701},{"pmid":32167747,"pmcid":"PMC7094171","title":"Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms.","text":["Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms.","The recent outbreak of coronavirus infectious disease 2019 (COVID-19) has gripped the world with apprehension and has evoked a scare of epic proportion regarding its potential to spread and infect humans worldwide. As we are in the midst of an ongoing pandemic of COVID-19, scientists are struggling to understand how it resembles and differs from the severe acute respiratory syndrome coronavirus (SARS-CoV) at the genomic and transcriptomic level. In a short time following the outbreak, it has been shown that, similar to SARS-CoV, COVID-19 virus exploits the angiotensin-converting enzyme 2 (ACE2) receptor to gain entry inside the cells. This finding raises the curiosity of investigating the expression of ACE2 in neurological tissue and determining the possible contribution of neurological tissue damage to the morbidity and mortality caused by COIVD-19. Here, we investigate the density of the expression levels of ACE2 in the CNS, the host-virus interaction and relate it to the pathogenesis and complications seen in the recent cases resulting from the COVID-19 outbreak. Also, we debate the need for a model for staging COVID-19 based on neurological tissue involvement.","ACS Chem Neurosci","Baig, Abdul Mannan","Khaleeq, Areeba","Ali, Usman","Syeda, Hira","32167747"],"abstract":["The recent outbreak of coronavirus infectious disease 2019 (COVID-19) has gripped the world with apprehension and has evoked a scare of epic proportion regarding its potential to spread and infect humans worldwide. As we are in the midst of an ongoing pandemic of COVID-19, scientists are struggling to understand how it resembles and differs from the severe acute respiratory syndrome coronavirus (SARS-CoV) at the genomic and transcriptomic level. In a short time following the outbreak, it has been shown that, similar to SARS-CoV, COVID-19 virus exploits the angiotensin-converting enzyme 2 (ACE2) receptor to gain entry inside the cells. This finding raises the curiosity of investigating the expression of ACE2 in neurological tissue and determining the possible contribution of neurological tissue damage to the morbidity and mortality caused by COIVD-19. Here, we investigate the density of the expression levels of ACE2 in the CNS, the host-virus interaction and relate it to the pathogenesis and complications seen in the recent cases resulting from the COVID-19 outbreak. Also, we debate the need for a model for staging COVID-19 based on neurological tissue involvement."],"journal":"ACS Chem Neurosci","authors":["Baig, Abdul Mannan","Khaleeq, Areeba","Ali, Usman","Syeda, Hira"],"date":"2020-03-14T11:00:00Z","year":2020,"_id":"32167747","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.1021/acschemneuro.0c00122","keywords":["ace2 tissue distribution","covid-19","coronavirus","sars-cov-2","host-virus interaction","spike protein"],"link_comment_in":"32233443","topics":["Mechanism"],"weight":1,"_version_":1666138490636599296,"score":45.16298},{"pmid":32353859,"title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.","text":["A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.","The novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 2.3 million people, killed over 160,000, and caused worldwide social and economic disruption(1,2). There are currently no antiviral drugs with proven clinical efficacy, nor are there vaccines for its prevention, and these efforts are hampered by limited knowledge of the molecular details of SARS-CoV-2 infection. To address this, we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins physically associated with each using affinity-purification mass spectrometry (AP-MS), identifying 332 high-confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds). Screening a subset of these in multiple viral assays identified two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the Sigma1 and Sigma2 receptors. Further studies of these host factor targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.","Nature","Gordon, David E","Jang, Gwendolyn M","Bouhaddou, Mehdi","Xu, Jiewei","Obernier, Kirsten","White, Kris M","O'Meara, Matthew J","Rezelj, Veronica V","Guo, Jeffrey Z","Swaney, Danielle L","Tummino, Tia A","Huettenhain, Ruth","Kaake, Robyn M","Richards, Alicia L","Tutuncuoglu, Beril","Foussard, Helene","Batra, Jyoti","Haas, Kelsey","Modak, Maya","Kim, Minkyu","Haas, Paige","Polacco, Benjamin J","Braberg, Hannes","Fabius, Jacqueline M","Eckhardt, Manon","Soucheray, Margaret","Bennett, Melanie J","Cakir, Merve","McGregor, Michael J","Li, Qiongyu","Meyer, Bjoern","Roesch, Ferdinand","Vallet, Thomas","Mac Kain, Alice","Miorin, Lisa","Moreno, Elena","Naing, Zun Zar Chi","Zhou, Yuan","Peng, Shiming","Shi, Ying","Zhang, Ziyang","Shen, Wenqi","Kirby, Ilsa T","Melnyk, James E","Chorba, John S","Lou, Kevin","Dai, Shizhong A","Barrio-Hernandez, Inigo","Memon, Danish","Hernandez-Armenta, Claudia","Lyu, Jiankun","Mathy, Christopher J P","Perica, Tina","Pilla, Kala B","Ganesan, Sai J","Saltzberg, Daniel J","Rakesh, Ramachandran","Liu, Xi","Rosenthal, Sara B","Calviello, Lorenzo","Venkataramanan, Srivats","Liboy-Lugo, Jose","Lin, Yizhu","Huang, Xi-Ping","Liu, YongFeng","Wankowicz, Stephanie A","Bohn, Markus","Safari, Maliheh","Ugur, Fatima S","Koh, Cassandra","Savar, Nastaran Sadat","Tran, Quang Dinh","Shengjuler, Djoshkun","Fletcher, Sabrina J","O'Neal, Michael C","Cai, Yiming","Chang, Jason C J","Broadhurst, David J","Klippsten, Saker","Sharp, Phillip P","Wenzell, Nicole A","Kuzuoglu, Duygu","Wang, Hao-Yuan","Trenker, Raphael","Young, Janet M","Cavero, Devin A","Hiatt, Joseph","Roth, Theodore L","Rathore, Ujjwal","Subramanian, Advait","Noack, Julia","Hubert, Mathieu","Stroud, Robert M","Frankel, Alan D","Rosenberg, Oren S","Verba, Kliment A","Agard, David A","Ott, Melanie","Emerman, Michael","Jura, Natalia","von Zastrow, Mark","Verdin, Eric","Ashworth, Alan","Schwartz, Olivier","d'Enfert, Christophe","Mukherjee, Shaeri","Jacobson, Matt","Malik, Harmit S","Fujimori, Danica G","Ideker, Trey","Craik, Charles S","Floor, Stephen N","Fraser, James S","Gross, John D","Sali, Andrej","Roth, Bryan L","Ruggero, Davide","Taunton, Jack","Kortemme, Tanja","Beltrao, Pedro","Vignuzzi, Marco","Garcia-Sastre, Adolfo","Shokat, Kevan M","Shoichet, Brian K","Krogan, Nevan J","32353859"],"abstract":["The novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 2.3 million people, killed over 160,000, and caused worldwide social and economic disruption(1,2). There are currently no antiviral drugs with proven clinical efficacy, nor are there vaccines for its prevention, and these efforts are hampered by limited knowledge of the molecular details of SARS-CoV-2 infection. To address this, we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins physically associated with each using affinity-purification mass spectrometry (AP-MS), identifying 332 high-confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds). Screening a subset of these in multiple viral assays identified two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the Sigma1 and Sigma2 receptors. Further studies of these host factor targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19."],"journal":"Nature","authors":["Gordon, David E","Jang, Gwendolyn M","Bouhaddou, Mehdi","Xu, Jiewei","Obernier, Kirsten","White, Kris M","O'Meara, Matthew J","Rezelj, Veronica V","Guo, Jeffrey Z","Swaney, Danielle L","Tummino, Tia A","Huettenhain, Ruth","Kaake, Robyn M","Richards, Alicia L","Tutuncuoglu, Beril","Foussard, Helene","Batra, Jyoti","Haas, Kelsey","Modak, Maya","Kim, Minkyu","Haas, Paige","Polacco, Benjamin J","Braberg, Hannes","Fabius, Jacqueline M","Eckhardt, Manon","Soucheray, Margaret","Bennett, Melanie J","Cakir, Merve","McGregor, Michael J","Li, Qiongyu","Meyer, Bjoern","Roesch, Ferdinand","Vallet, Thomas","Mac Kain, Alice","Miorin, Lisa","Moreno, Elena","Naing, Zun Zar Chi","Zhou, Yuan","Peng, Shiming","Shi, Ying","Zhang, Ziyang","Shen, Wenqi","Kirby, Ilsa T","Melnyk, James E","Chorba, John S","Lou, Kevin","Dai, Shizhong A","Barrio-Hernandez, Inigo","Memon, Danish","Hernandez-Armenta, Claudia","Lyu, Jiankun","Mathy, Christopher J P","Perica, Tina","Pilla, Kala B","Ganesan, Sai J","Saltzberg, Daniel J","Rakesh, Ramachandran","Liu, Xi","Rosenthal, Sara B","Calviello, Lorenzo","Venkataramanan, Srivats","Liboy-Lugo, Jose","Lin, Yizhu","Huang, Xi-Ping","Liu, YongFeng","Wankowicz, Stephanie A","Bohn, Markus","Safari, Maliheh","Ugur, Fatima S","Koh, Cassandra","Savar, Nastaran Sadat","Tran, Quang Dinh","Shengjuler, Djoshkun","Fletcher, Sabrina J","O'Neal, Michael C","Cai, Yiming","Chang, Jason C J","Broadhurst, David J","Klippsten, Saker","Sharp, Phillip P","Wenzell, Nicole A","Kuzuoglu, Duygu","Wang, Hao-Yuan","Trenker, Raphael","Young, Janet M","Cavero, Devin A","Hiatt, Joseph","Roth, Theodore L","Rathore, Ujjwal","Subramanian, Advait","Noack, Julia","Hubert, Mathieu","Stroud, Robert M","Frankel, Alan D","Rosenberg, Oren S","Verba, Kliment A","Agard, David A","Ott, Melanie","Emerman, Michael","Jura, Natalia","von Zastrow, Mark","Verdin, Eric","Ashworth, Alan","Schwartz, Olivier","d'Enfert, Christophe","Mukherjee, Shaeri","Jacobson, Matt","Malik, Harmit S","Fujimori, Danica G","Ideker, Trey","Craik, Charles S","Floor, Stephen N","Fraser, James S","Gross, John D","Sali, Andrej","Roth, Bryan L","Ruggero, Davide","Taunton, Jack","Kortemme, Tanja","Beltrao, Pedro","Vignuzzi, Marco","Garcia-Sastre, Adolfo","Shokat, Kevan M","Shoichet, Brian K","Krogan, Nevan J"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32353859","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1038/s41586-020-2286-9","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495618383872,"score":42.157562},{"pmid":32478897,"title":"Conditional Cell Reprogramming for Modeling Host-Virus Interactions and Human Viral Diseases.","text":["Conditional Cell Reprogramming for Modeling Host-Virus Interactions and Human Viral Diseases.","Conventional cancer and transformed cell lines are widely used in cancer biology and other fields within biology. These cells usually have abnormalities from the original tumor itself, but may also develop abnormalities due to genetic manipulation, or genetic and epigenetic changes during long term passages. Primary cultures may maintain lineage functions as the original tissue types, yet they have a very limited life span or population doubling time because of the nature of cellular senescence. Primary cultures usually have very low yields, and the high variability from any original tissue specimens, largely limiting their applications in research. Animal models are often used for studies of virus infections, disease modeling, development of antiviral drugs and vaccines. Human viruses often need a series of passages in vivo in order to adapt to the host environment because of variable receptors on the cell surface and may have intracellular restrictions from the cell types or host species. Here we describe a long term cell culture system, conditionally reprogrammed cells (CRCs), and its applications in modeling human viral diseases and drug discovery. Using feeder layer co-culture in presence of Y-27632 (conditional reprogramming, CR), CRCs can be obtained and rapidly propagated from surgical specimens, core or needle biopsies, and other minimally invasive or non-invasive specimens, for example, nasal cavity brushing. CRCs preserve their lineage functions, and provide biologically relevant and physiological conditions, which are suitable for studies of viral entry and replication, innate immune responses of host cells, and discovery of antiviral drugs. In this review, we summarize applications of CR technology in modeling host-virus interactions and human viral diseases, including SARS-CoV-2 and COVID-19, and anti-viral discovery. This article is protected by copyright. All rights reserved.","J Med Virol","Liu, Xuefeng","Mondal, Abdul M","32478897"],"abstract":["Conventional cancer and transformed cell lines are widely used in cancer biology and other fields within biology. These cells usually have abnormalities from the original tumor itself, but may also develop abnormalities due to genetic manipulation, or genetic and epigenetic changes during long term passages. Primary cultures may maintain lineage functions as the original tissue types, yet they have a very limited life span or population doubling time because of the nature of cellular senescence. Primary cultures usually have very low yields, and the high variability from any original tissue specimens, largely limiting their applications in research. Animal models are often used for studies of virus infections, disease modeling, development of antiviral drugs and vaccines. Human viruses often need a series of passages in vivo in order to adapt to the host environment because of variable receptors on the cell surface and may have intracellular restrictions from the cell types or host species. Here we describe a long term cell culture system, conditionally reprogrammed cells (CRCs), and its applications in modeling human viral diseases and drug discovery. Using feeder layer co-culture in presence of Y-27632 (conditional reprogramming, CR), CRCs can be obtained and rapidly propagated from surgical specimens, core or needle biopsies, and other minimally invasive or non-invasive specimens, for example, nasal cavity brushing. CRCs preserve their lineage functions, and provide biologically relevant and physiological conditions, which are suitable for studies of viral entry and replication, innate immune responses of host cells, and discovery of antiviral drugs. In this review, we summarize applications of CR technology in modeling host-virus interactions and human viral diseases, including SARS-CoV-2 and COVID-19, and anti-viral discovery. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Liu, Xuefeng","Mondal, Abdul M"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32478897","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26093","keywords":["air-liquid interface (ali)","cell senescence","conditional reprogramming","emerging viruses","functional models","normal cells","organoids","physiological conditions"],"locations":["vivo"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1668437835201380352,"score":40.025787}]}